Present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems
Background. Juvenile idiopathic arthritis is accompanied by severe functional disabilities refractory to standard treatment with methotrexate. Recently introduced genetic engineering has significantly improved the functional state of the patients with persistent disease and stopped the progressive d...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
Scientific Сentre for Family Health and Human Reproduction Problems
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b58c11e40cd94dd5a015953c76545188 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Background. Juvenile idiopathic arthritis is accompanied by severe functional disabilities refractory to standard treatment with methotrexate. Recently introduced genetic engineering has significantly improved the functional state of the patients with persistent disease and stopped the progressive destruction of joints. However, the risk of adverse reactions against the background of this type of therapy requires further study. Aims: to analyze the efficiency of the genetically engineered drugs applied at juvenile arthritis and undesirable effects of this treatment. Materials and methods. Long-term (7 years) observations of 141 patients aged from 8 months to 18 with juvenile idiopathic arthritis. Results. The article summarizes the experience of successful application of genetically engineered biological preparations (tocilizumab, abatacept, etanercept, adalimumab) in 33 patients out of 141 patients with juvenile arthritis observed in Irkutsk. Serious infections were not registered, but we detected cases of managed neutropenia in 2 out of 12 patients receiving tocilizumab. In one case (3 %) out of 33 patients receiving genetically engineered drugs, the drug was withdrawn because of the risk of tuberculosis. Rare cases of secondary inefficiency of such drugs as abatacept, etanercept, adalimumab have been revealed. The tactics of treating children with undesirable reactions to genetically engineered drugs is described. Conclusions. Genetic engineering therapy has shown a good effect in improving clinical and functional indices and stopping joint destructive damage. However, when using genetically engineered drugs in treatment, the safety issues should be evaluated. Nevertheless, in our study there were no serious adverse events. |
|---|